stars 1 stars 2 stars 3

ConicMeds is a biopharmaceutical company that develops a family of proprietary drug candidates (NanospacersTM) for the treatment of pathologies associated with cellular lipointoxication. Lipointoxications are characterized by an accumulation of saturated fatty acids in the membranes of the cells of our organism, which affects their proper functioning. These diseases include obstructive respiratory diseases, such as Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases (COPD), but also metabolic syndromes, responsible for Type 2 Diabetes, Hepatic Steatosis and certain cardiovascular diseases. The unique mode of action of NanospacersTM provides new therapeutic solutions to meet major public health challenges for which medical needs are not yet satisfied, as evidenced by the very high progression of respiratory and metabolic diseases throughout the world.

ConicMeds Development Questions

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users